Does The Orphan Drug Act Need A Facelift? Advocates Consider Changes
Rare disease advocates are wondering whether it may be time to strengthen the Orphan Drug Act and at least one organization is researching potential improvements that could be made to the pathway.
You may also be interested in...
If the debate does include a focus on entitlement spending, NORD does not plan on taking sides.
The group is afraid asking for wholesale changes to the law would invite too many problems, VP Dorman says at BIO.
Advocates and drug developers continue to call for an Orphan Drug Act renovation – not to add more years of marketing exclusivity, but to consider allowing easier and cheaper development programs.